ErVaccine Technologies
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $4.8Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2023-07-01attributed |
| Founded | 2019 |
| Headquarters | Lyon, France |
| Industry | biotech |
| Stage | seed |
| Website | ervaccinetechnologies.com |
ErVaccine Technologies develops therapeutic cancer vaccines and T-cell therapies that target tumor antigens derived from endogenous retroviruses. It aims to treat cancer patients by directing the immune system at a new family of non-conventional tumor antigens. Its endogenous-retrovirus target class opens vaccine and cell-therapy options beyond conventional antigens, spun out of Centre Léon Bérard in Lyon.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-07-01 | grant | $2.7M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $4.8M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | ervaccinetechnologies.com, read 2026-05-07 |
| Description | self-reported | ervaccinetechnologies.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.